May 9, 2022 -- Though gene therapy companies have been especially vulnerable to a public market downturn that's shaken the biotech sector, Bryan Poltilove, partner at BroadOak Capital Partners, remains "very bullish" on the fundamentals and the potential of the science.
Poltilove told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco that BroadOak's medium- to long-term investment strategy sees "great science" happening in the sector that's improving productivity and advancing cell and gene therapies, biologics, and other modalities.
BroadOak, which invests growth capital and provides investment banking services to companies operating in the life sciences tools, diagnostics, and biopharma services sectors, is an investor in ScienceBoard.net's parent company Science and Medicine Group.
Watch the video below to learn more.
Copyright © 2022 scienceboard.net